0.94
+0.032(+3.54%)
Currency In USD
| Previous Close | 0.9 |
| Open | 0.9 |
| Day High | 0.94 |
| Day Low | 0.89 |
| 52-Week High | 3.09 |
| 52-Week Low | 0.26 |
| Volume | 414,659 |
| Average Volume | 930,219 |
| Market Cap | 184.19M |
| PE | -4.93 |
| EPS | -0.19 |
| Moving Average 50 Days | 1.11 |
| Moving Average 200 Days | 1.2 |
| Change | 0.03 |
If you invested $1000 in Tevogen Bio Holdings Inc. (TVGN) since IPO date, it would be worth $94.21 as of August 23, 2025 at a share price of $0.936. Whereas If you bought $1000 worth of Tevogen Bio Holdings Inc. (TVGN) shares 2 years ago, it would be worth $86.95 as of August 23, 2025 at a share price of $0.936.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Tevogen Recognized in BINJE’s BEST Health Care 2025 for Advancing Health Equity and Sustainable Biopharma
GlobeNewswire Inc.
9 hours ago
WARREN, N.J., Aug. 22, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. (“Tevogen” or the “Company”) (Nasdaq: TVGN), announced today that it has been named in BINJE’s BEST Health Care 2025: Companies, Organizations and Service Providers. BINJE, a
REPEAT -- Tevogen Bio Enters Into Agreement for Up to $50 Million in Financing to Advance R&D and Clinical Development Efforts
GlobeNewswire Inc.
Aug 19, 2025 7:40 PM GMT
Includes $36 million line of credit and potential $14 million private placement WARREN, N.J., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. (“Tevogen” or “Tevogen Bio”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech
Tevogen Delivers Stronger Second Quarter and First Half 2025 Financial Results with Reduced Expenses and Growth Momentum
GlobeNewswire Inc.
Aug 19, 2025 4:10 PM GMT
Expenses significantly lower with expansion on multiple efforts; Q2 2025 loss from operations reduced to $5.4 million vs $8.6 million in Q2 2024.Tevogen maximizes capital efficiency, maintains access to financing to support growth, and anticipates re